HOME >> MEDICINE >> NEWS
Cure Rate Soars For Some AML Patients Receiving High-Dose Drug

COLUMBUS, Ohio -- A drug given at levels substantially higher than the standard dose can cure nearly five times as many patients who have a certain type of acute myeloid leukemia (AML), new research shows.

The study revealed that 78 percent of patients with “core binding factor” AML who received the drug cytarabine at high dose were in complete remission five years after treatment (and therefore potentially cured) compared to only 16 percent who received the standard dose.

“It is truly remarkable to achieve a cure rate of over 75 percent in a subgroup of adult leukemia patients; this rate approaches that for some types of childhood leukemia,” said Clara Bloomfield, director of Ohio State University's Comprehensive Cancer Center and William G. Pace III Professor of Cancer Research.

“Because high-dose cytarabine is quite toxic, especially for older people, we want to use it only with those patients who will benefit. These results tell us which patients we can cure, and which ones should receive other therapy.”

The finding is considered particularly strong because the study had followed patients for more than seven years after treatment; most such studies rely on models to project estimates of five-year remission rates.

The study, which was led by Bloomfield, appeared in the September issue of the journal Cancer Research. It involved 285 newly diagnosed AML patients aged 16 and older who were in remission. During the second phase of their treatment, a phase known as “intensification therapy,” the patients were randomly assigned to receive cytarabine at either standard dose (100 milligrams per square meter
'"/>

Contact: Clara Bloomfield
bloomfield-1@medctr.osu.edu
614-293-7518
Ohio State University
29-Oct-1998


Page: 1 2 3

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Patients with cancer have highly increased risk for blood clots
3. Patients with previous heart attacks may not benefit from pacemaker implant
4. Patients with cancer detected on screening mammography undergo less toxic treatment
5. Patients with moderate or severe hand dermatitis responsive to drug therapy
6. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
7. Patients who are intubated prior to hospital arrival fare worse find Pitt researchers
8. Patients undergoing weight loss surgery have high rates of H pylori bacteria
9. Patients with chronic sinus do not necessarily develop antibiotic resistance
10. Plastic surgeons honor Patients of Courage overcoming difficult obstacles, inspiring others
11. Patients with severe depression improve using guidelines developed by UT Southwestern researchers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cure Rate Soars For Some AML Patients Receiving High Dose Drug

(Date:7/28/2015)... ... ... Morristown Medical Center, part of Atlantic Health System, today announced it was ... the nation, to implant the newly approved CoreValve® Evolut® R System from Medtronic. The ... condition. , The CoreValve® Evolut® R System was approved by the U.S. Food and ...
(Date:7/28/2015)... Francisco, California (PRWEB) , ... July 28, 2015 , ... ... the results from a recent survey (1) examining consumers’ perspectives on digital ... June 17-24, 2015, covered topics such as innovations in digital health, level of trust ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Aziz Ahmad ... The talk took place from noon to 1 p.m. Tuesday, June 23, at the ... Fla. , Dr. Ahmad is board-certified in colorectal surgery and has more than ...
(Date:7/28/2015)... ... ... to Kxan on June 24th a previously FDA approved blood pressure medication ... isradipine has garnered national attention and is making drug and alcohol rehabilitation medical physicians ... The study was conducted by the University of Texas. Human trials may be set ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... Kinetic Data announced that Schneider Electric has completed its upgrade and expansion ... a global organization with more than 170,000 employees in 134 countries supplying a ...
Breaking Medicine News(10 mins):Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4
(Date:7/28/2015)... 2015  For many medical institutions and universities, commercializing ... inventors can be a constant challenge. Taking an idea ... are rare. A new company in ... Medical Device Investments (MDI) was created to commercialize ... physicians. MDI develops, manufactures and markets the products, with ...
(Date:7/28/2015)... , July 28, 2015   CSL ... for review a Marketing Authorization Application (MAA) for ... coagulation factor IX with recombinant albumin (rIX-FP) for ... people with Hemophilia B. Upon Swissmedic approval, rIX-FP ... treatment option with dosing intervals up to 14 ...
(Date:7/28/2015)... , July 28, 2015 VirtualScopics, Inc. (NASDAQ: ... imaging solutions, today announced that it will report its ... ET market close on Tuesday, August 11, 2015.  ... and Jim Groff , chief financial officer, will ... company,s financial results and provide a business update at ...
Breaking Medicine Technology:Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 3
Cached News: